The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.
Experts discuss screening, treatment, and other considerations in pediatric HCV.
Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.
Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.
The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.
Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.
Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.
Using an electronic health record-based can improve HCV screening rates among baby boomers.
FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.
Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients with rheumatic symptoms.
Fixed-dose ledipasvir-sofosbuvir plus weight-based ribavirin may offer a treatment alternative in treatment-naïve patients with non-cirrhotic GT3 HCV.
The FDA approved Vosevi for the retreatment of adults with chronic hepatitis C virus genotypes 1-6.
Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.
Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.
The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.
For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.
The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of hepatitis C virus.
A combination pill of sofosbuvir, velpatasvir, and voxilaprevir is nearly 100% effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents.
Next-generation metagenomic sequencing can detect a new RNA virus, human hepegivirus-1.
Hepatitis C virus infection may increase the risk for type 2 diabetes, but whether a causal relationship exists is unclear. Screening for type 2 diabetes in this population may have important public health implications.
Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.
Researchers evaluated the safety and efficacy of transplantation of kidneys from HCV genotype 1-viremic donors into HCV-negative patients, followed by elbasvir-grazoprevir (Zepatier) treatment.
Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.
Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.
The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.
Passage of the 2017 budget, along with congressional approval of the AHCA, leaves large holes in the funding of the proposed national approach to infectious disease control.
An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- Influenza Vaccine's Effectiveness Following Repeated Vaccination
- FDA Announces Orphan Drug Designation for HDV Drug
- New Single-Assay Test for Vaginitis Accurate as Traditional Tests
- Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat
- Bezlotoxumab Reduces 30-Day Hospital Readmissions for C difficile Infection
- FDA: Vabomere Approved for Complicated UTI Following Priority Review
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- New CDC Guidelines for SSI Prevention Leave Unanswered Questions
- Clinic Visits, Costs Decreased by Rotavirus Vaccination in US Children
- Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era
- FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis
- HIV Risk Behaviors More Prominent in Women With Mental Disorders
- Influenza Vaccine in Elderly Adults: Is High-Dose Better Than Standard-Dose?
- Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children